At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.13M, lower than 95% of all stocks globally
- PositionOperating margin is -8617.9%, lower than 95% of its Biotechnology peers (median -30.3%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.87BEUR7.55B · vs all stocks (USD)
Revenue (TTM)
4.67MEUR5.13M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.2320xvs all stocks
52-Week Change
-3.55%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
6.87BEUR7.55B · vs all stocks (USD)
Enterprise Value
5.88BEUR6.46B · vs all stocks (USD)
Forward P/E
-27.16xvs Biotechnology peers
Price to Book (MRQ)
17.15xvs Biotechnology peers
Enterprise to Revenue
1.26Kxvs Biotechnology peers
Enterprise to EBITDA
-20.17xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-62.88%vs Biotechnology peers
Return on Equity (TTM)
-252.35%vs Biotechnology peers
Revenue (TTM)
4.67MEUR5.13M · vs all stocks (USD)
Revenue per Share (TTM)
0.0600EURUpdated Oct 24, 2026Quarterly Revenue Growth
-6.80%vs Biotechnology peers
Gross Profit (TTM)
4.67MEUR5.13M · vs all stocks (USD)
EBITDA (TTM)
-291.55MEUR-320.32M · vs all stocks (USD)
Net Income (TTM)
-401.22MEUR-440.81M · vs all stocks (USD)
Operating Cash Flow (TTM)
-197.02MEUR-216.46M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-125.90MEUR-138.32M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00EURUpdated Oct 24, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00EURFY2025 · Dec 31, 2025Operating Income
-246.06MEUR-270.34M · vs all stocks (USD)
Pre-tax Income
-330.25MEURFY2025 · Dec 31, 2025Income Tax Expense
5.85MEURFY2025 · Dec 31, 2025Net Income
-336.10MEURFY2025 · Dec 31, 2025EBIT
-301.77MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-268.99MEURFY2025 · Dec 31, 2025Research & Development
177.76MEURFY2025 · Dec 31, 2025Selling, General & Administrative
72.86MEURFY2025 · Dec 31, 2025Other Operating Expenses
-4.57MEURFY2025 · Dec 31, 2025Non-operating Interest Income
5.75MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
28.48MEURFY2025 · Dec 31, 2025EPS (Basic)
-4.83EURFY2025 · Dec 31, 2025EPS (Diluted)
-4.83EURFY2025 · Dec 31, 2025Basic Shares Outstanding
69.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
69.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-336.10MEURFY2025 · Dec 31, 2025Operating Cash Flow
-270.21MEURFY2025 · Dec 31, 2025Free Cash Flow
-270.35MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
516.68MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-336.10MEURFY2025 · Dec 31, 2025Depreciation & Amortization
1.07MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.85MEURFY2025 · Dec 31, 2025Stock-based Compensation
35.40MEURFY2025 · Dec 31, 2025Other Non-cash Items
22.03MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
7.04MEURFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.21MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
710.00KEURFY2025 · Dec 31, 2025Capital Expenditures
-142.00KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00EURFY2025 · Dec 31, 2025Other Investing Activity
-13.58MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.72MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00EURFY2025 · Dec 31, 2025Long-term Debt Payments
-59.53MEURFY2025 · Dec 31, 2025Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
-40.61MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
547.98MEURFY2025 · Dec 31, 2025Shares Outstanding
79.29MSharesUpdated Oct 24, 2026Float Shares
65.02MSharesUpdated Oct 24, 2026% Held by Insiders
3.96%vs all stocks
% Held by Institutions
52.91%vs all stocks
Total Cash (MRQ)
402.38MEUR442.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.04EURUpdated Oct 24, 2026Total Debt (MRQ)
1.21MEUR1.33M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0033xvs Biotechnology peers
Current Ratio (MRQ)
5.96xvs Biotechnology peers
Book Value per Share (MRQ)
4.59EURUpdated Oct 24, 2026Total Assets
584.34MEUR642.00M · vs all stocks (USD)
Total Current Assets
551.24MEURFY2025 · Dec 31, 2025Total Liabilities
129.14MEURFY2025 · Dec 31, 2025Total Non-current Assets
33.10MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
66.11MEURFY2025 · Dec 31, 2025Total Current Liabilities
63.02MEURFY2025 · Dec 31, 2025Cash
38.14MEURFY2025 · Dec 31, 2025Cash Equivalents
478.54MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
516.68MEURFY2025 · Dec 31, 2025Other Short-term Investments
13.70MEURFY2025 · Dec 31, 2025Accounts Payable
37.55MEURFY2025 · Dec 31, 2025Short-term Debt
1.30MEURFY2025 · Dec 31, 2025Deferred Revenue
0.00EURFY2025 · Dec 31, 2025Long-term Debt
554.00KEURFY2025 · Dec 31, 2025Other Non-current Liabilities
30.24MEURFY2025 · Dec 31, 2025Common Stock (Book)
785.00KEURFY2025 · Dec 31, 2025Retained Earnings
-738.48MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
455.20MEUR500.12M · vs all stocks (USD)
52-Week Low
60.45EURUpdated Oct 24, 202652-Week High
139.00EURUpdated Oct 24, 202652-Week Change
-3.55%vs all stocks
Beta
-0.2320xvs all stocks
50-Day MA
90.81EURUpdated Oct 24, 2026200-Day MA
99.67EURUpdated Oct 24, 2026Avg 10-Day Volume
109.82KSharesUpdated Oct 24, 2026Avg 30-Day Volume
124.15KSharesUpdated Oct 24, 2026Diluted EPS (TTM)
-5.21EURUpdated Oct 24, 2026Other Income / Expense
-31.71MEURFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -8617.9%, lower than 95% of its Biotechnology peers (median -30.3%)Significant
Operating margin: -86.18Industry median: -0.30Industry P5: -44.30Peers compared: 245
Return on equity is -252.3%, lower than 95% of its Biotechnology peers (median -21.1%)Significant
Return on equity: -2.52Industry median: -0.21Industry P5: -1.59Peers compared: 245
Price-to-book is 17.15×, higher than 95% of its Biotechnology peers (median 2.68×)Significant
Price-to-book: 17.15Industry median: 2.68Industry P95: 15.61Peers compared: 245
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 245
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.13M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,128,638.24Global P5: 37,231,057.061
Market cap is $7.55B, above the global median of $1.14BNotable
Market cap (USD): 7,546,029,803.598Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Praxis Precision Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule